FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 巨子生物控股有限公司 呈交日期： 2026年1月16日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02367 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件 ...

Core Insights - The article highlights the evolving consumer demand for skincare products, emphasizing the importance of long-term skin safety and the role of advanced technology in meeting these needs. The company, Giant Bio, is positioned as a leader in the recombinant collagen field, redefining the value of biotech firms in the eyes of consumers [1] Group 1: Clinical Evidence and Trust - Giant Bio establishes a foundation of trust through clinical data supporting its recombinant collagen technology. At the CDA2025 conference, research showed significant improvement in facial erythema for patients using products containing recombinant collagen, providing clear, visual results that shift consumer choice from marketing claims to scientifically backed evidence [3] - The transition from potential effectiveness to confirmed effectiveness represents the core value that Giant Bio creates for consumers [3] Group 2: Professional Application and Safety - In the specialized post-aesthetic care scenario, consumer demands are more stringent. Giant Bio extended its product efficacy validation to professional fields such as laser skin repair, exploring solutions through extensive research and clinical evidence. This indicates that choosing Giant Bio means opting for a clinically validated safety solution [4] - The application research on infant vascular tumors further underscores the brand's commitment to safety [4] Group 3: Emotional Connection and Brand Differentiation - Beyond addressing skin issues, Giant Bio integrates emotional needs into its product offerings through initiatives like "My 'Recombinant' Relationship," showcasing deep insights into consumer psychology [5] - The brand's "Health Living Toolbox" concept merges high-tech products with everyday care, breaking down the barriers between professional and daily use. This strategy enhances product convenience and allows technological innovation to gently enter consumers' lives [7] - The focus on emotional health transforms products from mere functional attributes into a part of users' self-identity, establishing a unique differentiation advantage in a competitive market [7] Group 4: Transparency and Consumer Assurance - In an era of increasing information transparency, the scientific research behind Giant Bio's recombinant collagen provides consumers with clear value references. The combination of scientific evidence, professional application, and innovative emotional engagement forms a strong bond between the brand and its users [9] - The practice of making advanced technology accessible not only translates into products but also ensures that consumers feel assured and confident in every usage scenario [9]

Group 1 - The core point of the news is that Juzi Biotechnology has received approval from the National Medical Products Administration for its recombinant type I α1 collagen and sodium hyaluronate composite solution, marking a significant advancement in the high-end medical aesthetics regenerative materials sector [1][2] - The newly approved product is intended for injection into the dermis, primarily aimed at improving the smoothness of the cheeks, addressing a clear clinical need with limited supply in the market [1] - This product is the world's first implant that combines "recombinant collagen" and "sodium hyaluronate," potentially creating a new paradigm in facial rejuvenation treatments through a synergistic effect of "immediate filling + long-lasting regeneration" [1] Group 2 - Juzi Biotechnology holds two Class III medical device registration certificates in the medical aesthetics field, both of which have passed a stringent dual review process by the National Medical Products Administration, indicating superior safety, efficacy, and quality control [2] - The company leverages its synthetic biology technology platform to achieve breakthroughs in high-end regenerative materials, aligning with national strategic emerging industry directions [2] - There is an expectation for Juzi Biotechnology to accelerate the launch of more innovative products, contributing to the development of the biomanufacturing industry in China [2]

Core Viewpoint - CICC maintains a "outperforming the industry" rating for Giant Bio (02367) with a target price of HKD 56, indicating a 55% upside potential based on 25/23x P/E for 2026-2027 [1] Recent Events - On January 15, Giant Bio announced the approval of its "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution" as a Class III medical device, marking it as the world's first product aimed at improving cheek smoothness [2] - The approval of this product is expected to expand the company's aesthetic medicine product matrix and validate its leading technological research and development capabilities [2] Future Product Pipeline - The company has a rich pipeline for aesthetic medicine, with cross-linked neck wrinkle products receiving priority review status and cross-linked nasolabial fold products progressing smoothly [3] - The approval of the first two aesthetic products has confirmed the company's technological leadership and safety, with strong channel resources and operational experience expected to enhance future product launches [3] Cosmetics Product Matrix and Channel Expansion - The company has a clear plan for product and channel expansion, with a rich reserve of new products including the "Kemei" collagen repair series and plans for brand upgrades and new product launches in 2026 [4] - In terms of marketing, the company has strengthened its collaboration with key influencers, such as launching a New Year gift box with Li Jiaqi, and plans to enhance its online influencer matrix and self-operated team while expanding offline coverage [4]

Core Viewpoint - Company maintains a "outperforming the industry" rating for Giant Bio (02367) with a target price of HKD 56, indicating a potential upside of 55% based on 26-27 P/E ratios of 25x and 23x respectively, supported by strong R&D capabilities, brand recognition, and team cohesion [1] Recent Events - The company announced on January 15 that its "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution" has been approved as a Class III medical device, marking it as the world's first product aimed at improving cheek smoothness [2][3] - The approval is expected to expand the company's aesthetic product matrix and validate its leading technological R&D capabilities [2] Future Product Pipeline - The company has a rich pipeline of aesthetic products, including cross-linked neck wrinkle products that have received priority review status and cross-linked nasolabial fold products that are progressing smoothly [3] - The approval of the first two aesthetic products has confirmed the company's technological leadership and safety, with strong channel resources and operational experience that can be reused for future product launches [3] Cosmetics Product Matrix and Channel Expansion - The company has a clear plan for product and channel expansion, with a rich reserve of new products including the "Kefumei Collagen Repair," "Focus," and "Order" series set to launch [4] - The company plans to upgrade the "Keli Jin" brand and introduce new products by 2026, while also enhancing collaboration with key influencers like Li Jiaqi for promotional activities [4] - There is a focus on strengthening online influencer networks and self-operated teams, as well as expanding offline channels including cinema lines, OTC, and CS/KA channel coverage [4]

Core Viewpoint - The approval of the recombinant type I α1 collagen and sodium hyaluronate composite solution by the National Medical Products Administration of China marks a significant milestone for the company, enhancing its position in the aesthetic medicine market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Shaanxi Juzhi Biotechnology Co., Ltd., received the Medical Device Registration Certificate for the new product, which is the first of its kind globally for improving cheek smoothness [1] - The product is primarily composed of recombinant collagen and sodium hyaluronate, intended for injection into the dermis [1] Group 2: Market Impact - The stock price of the company increased by 5.38%, reaching HKD 37.84, with a trading volume of HKD 16.51 million [1] - CICC expressed optimism regarding the product's approval, which is expected to further expand the company's aesthetic product portfolio and validate its leading technological research and development capabilities [1] Group 3: Future Strategy - The company plans to steadily advance the product's market launch and promotion through a diversified product mix, comprehensive channel network, and refined brand management [1] - The aim is to provide differentiated solutions and continuously strengthen its leading market position in the health and beauty sector [1]

Core Viewpoint - The approval of the recombinant type I α1 collagen and sodium hyaluronate composite solution by the National Medical Products Administration of China marks a significant milestone for the company, enhancing its position in the aesthetic medicine market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Shaanxi Juzhi Biotechnology Co., Ltd., received the Medical Device Registration Certificate for the composite solution, which is the first of its kind globally for improving cheek smoothness [1] - The product is primarily composed of recombinant collagen and sodium hyaluronate, intended for injection into the dermis [1] Group 2: Market Impact - The stock price of the company increased by 5.38%, reaching HKD 37.84, with a trading volume of HKD 16.51 million following the announcement [1] - CICC expressed optimism regarding the product's approval, which is expected to further expand the company's aesthetic product matrix and validate its leading technological research and development capabilities [1] Group 3: Future Strategy - The company plans to steadily advance the product's market launch and promotion through a diversified product portfolio, comprehensive channel network, and refined brand operations [1] - The aim is to provide differentiated solutions and continuously strengthen its leading market position in the health and beauty sector [1]

证券时报·数据宝统计显示，1月15日有42家香港上市公司进行了股份回购，合计回购2844.54万股，回购 金额9.45亿港元。 | 01317 | 枫叶教育 | 290.20 | 111.73 | 0.385 | 0.385 | 220.37 | | --- | --- | --- | --- | --- | --- | --- | | 01066 | 威高股份 | 18.00 | 99.08 | 5.520 | 5.490 | 2859.04 | | 01497 | 燕之屋 | 15.00 | 92.73 | 6.280 | 6.060 | 92.73 | | 02598 | 连连数字 | 13.00 | 90.95 | 7.150 | 6.930 | 698.04 | | 01600 | 天伦燃气 | 28.00 | 82.09 | 2.930 | 2.910 | 932.08 | | 06831 | 绿茶集团 | 10.60 | 74.33 | 7.120 | 6.960 | 848.83 | | 09959 | 联易融科 | 28.80 | 73.71 | 2.570 | 2.530 | 170.07 ...

Major Events - Giant Bio (02367) received the Medical Device Registration Certificate from the National Medical Products Administration for its recombinant type I α1 collagen and sodium hyaluronate composite solution [1] - Jitu Express-W (01519) plans to subscribe for 226 million H shares of SF Holding and issue 822 million Class B shares to SF Holding [1] - Zijin Mining (02899) signed a cooperation and equity transfer agreement for the Shapingou Molybdenum Mine project [1] - Jiangxi Copper (00358) subsidiary signed an Investment Option Agreement with First Quantum for exploration cooperation in Kazakhstan's mining projects [1] - Derin Holdings (01709) received conditional approval from the CSRC for Derin Securities to provide virtual asset consulting services [1] - GAC Group (02238) subsidiary GAC Trumpchi received 100 million yuan in funding for industrial transformation and development [1] - Juteng International (03336) suspected of a cyber attack and has initiated a comprehensive investigation [1] Operating Performance - China Southern Airlines (01055) increased passenger capacity input by 11.89% year-on-year in December [1] - Air China (00753) reported a 10% year-on-year increase in passenger turnover in December [1] - China Eastern Airlines (00670) saw a 7.61% year-on-year increase in passenger turnover in December [1] - China Metallurgical Group (01618) new contract amount for 2025 is 1,113.6 billion yuan, a decrease of 10.8% year-on-year [1] - ZhongAn Online (06060) projected total original insurance premium income of approximately 35.643 billion yuan for 2025, an increase of 6.66% year-on-year [1] - China General Nuclear Power Corporation (01164) produced a total of 702.5 tons of natural uranium in the fourth quarter [1] - Jiuxing Holdings (01836) reported a 0.8% year-on-year increase in comprehensive income to 388.6 million USD in the fourth quarter [1] - Luoyang Molybdenum (03993) issued a profit warning, expecting annual net profit attributable to shareholders to be between 20 billion and 20.8 billion yuan, an increase of 47.80% to 53.71% year-on-year [1] - Chongqing Iron and Steel (01053) issued a profit warning, expecting a net loss of 2.5 billion to 2.8 billion yuan for 2025 [1] - Huiju Technology (01729) issued a profit warning, expecting annual net profit to increase by approximately 60% to 70% year-on-year [1]

| 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2026.01.15 | 40.00 | 36.100 | 35.440 | 1434.67 | | 2026.01.14 | 40.00 | 35.800 | 35.100 | 1415.00 | | 2026.01.13 | 40.00 | 36.200 | 35.640 | 1433.78 | | 2026.01.12 | 40.00 | 35.500 | 34.500 | 1400.29 | | 2026.01.09 | 40.00 | 34.580 | 34.240 | 1375.96 | | 2026.01.08 | 40.00 | 34.440 | 34.120 | 1371.06 | | 2026.01.07 | 40.00 | 34.680 | 34.300 | 1378.34 | | 2026.01.06 | 40.00 | 34.480 | 33.840 | 1366.93 | | 2026.01.05 | 40. ...